Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.